What is the share price of Kopran Ltd (KOPRAN) today?
The share price of KOPRAN as on 18th September 2026 is ₹277.60. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Kopran Ltd (KOPRAN) share?
The past returns of Kopran Ltd (KOPRAN) share are- Past 1 week: 19.64%
- Past 1 month: 35.41%
- Past 3 months: 50.23%
- Past 6 months: 135.63%
- Past 1 year: 60.69%
- Past 3 years: 18.48%
- Past 5 years: 31.01%
What are the peers or stocks similar to Kopran Ltd (KOPRAN)?
The peers or stocks similar to Kopran Ltd (KOPRAN) include:What is the dividend yield % of Kopran Ltd (KOPRAN) share?
The current dividend yield of Kopran Ltd (KOPRAN) is 1.08.What is the market cap of Kopran Ltd (KOPRAN) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Kopran Ltd (KOPRAN) is ₹1341.53 Cr as of 18th September 2026.What is the 52 week high and low of Kopran Ltd (KOPRAN) share?
The 52-week high of Kopran Ltd (KOPRAN) is ₹282.10 and the 52-week low is ₹107.What is the PE and PB ratio of Kopran Ltd (KOPRAN) stock?
The P/E (price-to-earnings) ratio of Kopran Ltd (KOPRAN) is 52.14. The P/B (price-to-book) ratio is 2.53.Which sector does Kopran Ltd (KOPRAN) belong to?
Kopran Ltd (KOPRAN) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Kopran Ltd (KOPRAN) shares?
You can directly buy Kopran Ltd (KOPRAN) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Kopran Ltd
KOPRAN Share Price
NSEKOPRAN Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
BadThe stock is overpriced and in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
KOPRAN Performance & Key Metrics
KOPRAN Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 53.68 | 2.53 | 1.08% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 47.16 | 5.92 | 0.48% |
KOPRAN Analyst Ratings & Forecast
Price Upside
Earnings Growth
Rev. Growth
KOPRAN Company Profile
Kopran Limited is engaged in pharmaceutical business. The Company's business units include Finished Dosage Forms, Active Pharmaceutical Ingredients, Research and Development, and Consumer Healthcare.
KOPRAN Sentiment Analysis
KOPRAN Sentiment Analysis
KOPRAN Stock Summary · March 2025
Kopran Limited is strategically merging with Kopran Laboratories to enhance its foothold in the burgeoning Indian diagnostic market, projected to reach $25 billion by FY '28. This merger, aimed at creating synergies and improving margins through efficient manufacturing of diagnostic kits, reflects management's optimism about future growth, particularly in the healthcare sector. Despite a strong year-over-year revenue increase, the company faces challenges in diversifying its revenue streams, heavily reliant on its clinical chemistry segment. Engaging actively with investors, management has addressed concerns regarding valuation while emphasizing a robust operational strategy focused on B2B opportunities in underserved markets. With plans for significant capital investment and a commitment to service delivery, Kopran is well-positioned to capitalize on the industry's projected growth of 14% to 15%.
KOPRAN Stock Growth Drivers
KOPRAN Stock Growth Drivers
6Merger and Synergies
Kopran Limited is in the process of merging with Kopran Laboratories, aiming to create synergies
Financial Performance and Growth
Kopran Laboratories reported a turnover of approximately INR 68-69 crores for the first nine months,
KOPRAN Stock Challenges
KOPRAN Stock Challenges
3Muted Revenue Performance
The company has reported muted revenue performance for the December period compared to the previous
Seasonality Concerns
There are concerns regarding the seasonality of the company's revenue, as the December period's performance
KOPRAN Forecast
KOPRAN Forecasts
KOPRAN
KOPRAN
Income
Balance Sheet
Cash Flow
KOPRAN Income Statement
KOPRAN Income Statement
| Quarter | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | jun 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 195.75 | 142.06 | 152.56 | 166.41 | 175.62 | 137.77 | 117.93 | 194.35 | 234.11 | 156.05 | ||||||||||
| Operating & Other expenses | 164.39 | 121.27 | 136.82 | 146.40 | 155.28 | 121.09 | 123.19 | 176.52 | 201.07 | 138.19 | ||||||||||
| EBITDA | 31.36 | 20.79 | 15.74 | 20.01 | 20.34 | 16.68 | -5.26 | 17.83 | 33.04 | 17.86 | ||||||||||
| Depreciation/Amortization | 3.59 | 3.87 | 3.85 | 4.00 | 3.87 | 4.26 | 4.28 | 4.42 | 4.52 | 5.77 | ||||||||||
| PBIT | 27.77 | 16.92 | 11.89 | 16.01 | 16.47 | 12.42 | -9.54 | 13.41 | 28.52 | 12.09 | ||||||||||
| Interest & Other Items | 2.59 | 2.18 | 2.23 | 2.16 | 2.77 | 2.54 | 2.09 | 2.67 | 3.17 | 3.28 | ||||||||||
| PBT | 25.18 | 14.74 | 9.66 | 13.85 | 13.70 | 9.88 | -11.63 | 10.74 | 25.35 | 8.81 | ||||||||||
| Taxes & Other Items | 6.55 | 3.64 | 2.26 | 3.46 | 4.03 | 2.44 | -1.70 | 1.40 | 6.48 | 2.10 | ||||||||||
| Net Income | 18.63 | 11.10 | 7.40 | 10.39 | 9.67 | 7.44 | -9.93 | 9.34 | 18.87 | 6.71 | ||||||||||
| EPS | 3.86 | 2.30 | 1.53 | 2.16 | 2.00 | 1.54 | -2.06 | 1.93 | 3.91 | 1.39 |
KOPRAN Company Updates
Investor Presentation
KOPRAN Stock Peers
KOPRAN Past Performance & Peer Comparison
KOPRAN Past Performance & Peer Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Kopran Ltd | 52.14 | 2.53 | 1.08% |
| Sun Pharmaceutical Industries Ltd | 38.40 | 5.26 | 0.87% |
| Torrent Pharmaceuticals Ltd | 85.10 | 10.47 | 0.70% |
| Zydus Lifesciences Ltd | 22.96 | 3.91 | 0.09% |
KOPRAN Stock Price Comparison
Compare KOPRAN with any stock or ETFKOPRAN Holdings
KOPRAN Shareholdings
KOPRAN Promoter Holdings Trend
KOPRAN Promoter Holdings Trend
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant
KOPRAN Institutional Holdings Trend
KOPRAN Institutional Holdings Trend
In last 3 months, retail holding in the company has decreased by 2.03%
In last 3 months, foreign institutional holding of the company has almost stayed constant
KOPRAN Shareholding Pattern
KOPRAN Shareholding Pattern
KOPRAN Shareholding History
KOPRAN Shareholding History
Mutual Funds Invested in KOPRAN
Mutual Funds Invested in KOPRAN
No mutual funds holding trends are available
Top 1 Mutual Funds holding Kopran Ltd
| Funds (Top 1) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0006% | Percentage of the fund’s portfolio invested in the stock 0.04% | Change in the portfolio weight of the stock over the last 3 months 0.00% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 110/130 (+2) |
Compare 3-month MF holding change on Screener
smallcases containing KOPRAN stock
smallcases containing KOPRAN stock
Looks like this stock is not in any smallcase yet.
KOPRAN Events
KOPRAN Events
KOPRAN Dividend Trend
KOPRAN has increased or maintained dividend levels over the last 5 years
Current dividend yield is 1.08%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹10.80 every year
Dividends
Corp. Actions
Announcements
Legal Orders
KOPRAN Dividend Trend
KOPRAN has increased or maintained dividend levels over the last 5 years
Current dividend yield is 1.08%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹10.80 every year
KOPRAN Upcoming Dividends
KOPRAN Upcoming Dividends
No upcoming dividends are available
KOPRAN Past Dividends
KOPRAN Past Dividends
Cash Dividend
Ex DateEx DateAug 11, 2026
Dividend/Share
₹3.00
Ex DateEx Date
Aug 11, 2026
Cash Dividend
Ex DateEx DateSep 4, 2025
Dividend/Share
₹3.00
Ex DateEx Date
Sep 4, 2025
Cash Dividend
Ex DateEx DateSep 2, 2024
Dividend/Share
₹3.00
Ex DateEx Date
Sep 2, 2024
Cash Dividend
Ex DateEx DateSep 7, 2023
Dividend/Share
₹3.00
Ex DateEx Date
Sep 7, 2023
Cash Dividend
Ex DateEx DateAug 4, 2022
Dividend/Share
₹3.00
Ex DateEx Date
Aug 4, 2022
KOPRAN Stock News & Opinions
KOPRAN Stock News & Opinions
Kopran Limited informed the BSE Limited and National Stock Exchange of India Ltd. that its Corporate Affairs Committee approved the allotment of 40,500 equity shares to eligible employees upon exercise of options under the Kopran Employee Stock Option Plan 2023 (“ESOP 2023”/ “Plan”), with an exercise price of Rs 179 per share. Consequently, the company's paid-up equity share capital increased from Rs 482,856,050 to Rs 483,261,050, representing 48,326,105 equity shares.
Kopran Ltd share price softened by 2.78% to Rs 190.4 after the company's net profit plunged by 64.49% to Rs 6.7 crore, while revenue from operations nosedived 34.20% to Rs 153.99 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.84 lakh crore, easing 5.32%. It has inched up 0.53% over last one week and climbed by 11.64% in last one month while the market capitalization of Kopran Ltd has eased by 0.76% and 17.97% in the same period respectively. Profit before tax (PBT) of Kopran Ltd stood at Rs 8.8 crore in Q2 FY26, retreating 11.02% year-on-year, and plunging by 65.29% quarter-on-quarter. EBITDA came in at Rs 14 crore, rallying 18.84% YoY and tumbling by 58.16% sequentially. Total expenses saw a steep drop of 29.98% to Rs 143.96 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 120.89 crore, falling by 13.61% YoY, while employee benefits expense was at Rs 18.46 crore, jumping 12.15% YoY. For the TTM ended FY26, revenue from operations posted a slight growth of 8.23% to Rs 681.42 crore, while net profit tanked by 33.26% to Rs 25.73 crore, compared to previous TTM. EBITDA jumped by 6980% to Rs 61.6 crore, and PBT collapsed by 33.86% to Rs 34.36 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 66.75 crore in FY26, as against Rs 41.94 crore in FY25. Kopran Ltd surged by 20.20% in last one year, significantly outperforming the benchmark BSE Sensex which has softened by 1.97% during the same period.
Kopran will hold a meeting of the Board of Directors of the Company on 7 August 2026.
Kopran announced that the Annual General Meeting(AGM) of the company will be held on 18 August 2026.
Net profit of Kopran rose 94.94% to Rs 18.87 crore in the quarter ended March 2026 as against Rs 9.68 crore during the previous quarter ended March 2025. Sales rose 35.77% to Rs 234.02 crore in the quarter ended March 2026 as against Rs 172.36 crore during the previous quarter ended March 2025. For the full year,net profit declined 33.26% to Rs 25.73 crore in the year ended March 2026 as against Rs 38.55 crore during the previous year ended March 2025. Sales rose 8.23% to Rs 681.42 crore in the year ended March 2026 as against Rs 629.60 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales234.02172.36 36 681.42629.60 8 OPM %14.089.92 -9.0911.58 - PBDT29.8617.58 70 51.8367.54 -23 PBT25.3513.71 85 34.3651.95 -34 NP18.879.68 95 25.7338.55 -33 Powered by Capital Market - Live
Kopran announced that the Board of Directors of the Company at its meeting held on 19 May 2026, inter alia, have recommended the final dividend of Rs 3 per equity Share (i.e. 30%) , subject to the approval of the shareholders.
Kopran will hold a meeting of the Board of Directors of the Company on 19 May 2026.
Kopran announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 3 June 2026.
Kopran will hold a meeting of the Board of Directors of the Company on 22 January 2026.Powered by Capital Market - Live
Net loss of Kopran reported to Rs 9.92 crore in the quarter ended September 2025 as against net profit of Rs 7.38 crore during the previous quarter ended September 2024. Sales declined 22.20% to Rs 117.91 crore in the quarter ended September 2025 as against Rs 151.56 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales117.91151.56 -22 OPM %-4.489.72 - PBDT-7.3413.50 PL PBT-11.639.64 PL NP-9.927.38 PL Powered by Capital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 5.99%, vs industry avg of 11.78%
Over the last 5 years, market share decreased from 0.17% to 0.13%
Over the last 5 years, net income has grown at a yearly rate of -16.02%, vs industry avg of 10.53%